| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Neurodazine targets Wnt and Shh (Sonic Hedgehog) signaling pathways, which are critical for neural development and neurogenesis. By activating these pathways, Neurodazine promotes neurogenesis in pluripotent cells. Wnt signaling is involved in cell proliferation, differentiation, and neuronal fate determination. Shh signaling is essential for neural tube patterning and neuronal differentiation. Neurodazine also has neuroprotective effects, protecting against oxidative stress-induced cellular damage.
|
|---|---|
| ln Vitro |
P19 cells treated with neurodazine (5 μM; 1–10 days) exhibit markers unique to neurons [1]. Neurodazine specifically prevents P19 cells from differentiating into astrocytes [1].
In vitro, Neurodazine promotes neurogenesis in pluripotent cells by activating Wnt and Shh signaling pathways. It enhances neurite outgrowth and supports synaptic plasticity. The compound is a neurogenic inducer. It protects against oxidative stress-induced cellular damage. Detailed in vitro data are available in the primary literature. Neurodazine is a valuable tool for neurogenesis research. |
| ln Vivo |
In vivo data for Neurodazine are limited in publicly available sources. Based on its in vitro neurogenic and neuroprotective activities, the compound is expected to be useful for in vivo studies of neurogenesis and neuroprotection. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile. The compound is a research tool for neuroscience research.
|
| Enzyme Assay |
In vitro neurogenesis assays for Neurodazine typically use pluripotent stem cells (e.g., embryonic stem cells, iPSCs) or neural progenitor cells. Cells are cultured in appropriate medium and treated with Neurodazine at various concentrations (0.1-100 μM) for 3-14 days. Neurogenesis is assessed by immunostaining for neuronal markers (e.g., βIII-tubulin, NeuN, MAP2). Neurite outgrowth is measured by image analysis. Wnt and Shh pathway activation is assessed by reporter assays or Western blotting. Cell viability is assessed by standard assays. IC₅₀ and EC₅₀ values are calculated from dose-response curves. Controls include vehicle and known neurogenic inducers.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: P19 Cell Tested Concentrations: 5 μM Incubation Duration: 1-10 days Experimental Results: Induced expression of neuron-specific markers. For cell-based assays, pluripotent stem cells or neural progenitor cells are cultured in appropriate medium. Cells are seeded in multi-well plates and treated with Neurodazine at various concentrations for 3-14 days. Neurogenesis is assessed by immunostaining for neuronal markers. Neurite outgrowth is measured by image analysis. Synaptic plasticity markers are assessed by Western blotting. Oxidative stress protection is assessed by ROS measurement after oxidative stress induction. All treatments include vehicle controls and are performed in triplicate. |
| Animal Protocol |
In vivo, Neurodazine may be administered to rodents via intraperitoneal (IP) or intravenous (IV) injection. The compound is formulated in a suitable vehicle such as DMSO, PEG, or saline-based solutions. For neurogenesis or neuroprotection models, animals are dosed at various regimens. Endpoints include immunohistochemical analysis of neurogenesis markers, behavioral assessments, and tissue histology. Blood and tissue samples are collected for pharmacokinetic and pharmacodynamic analysis. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Neurodazine (MW 456.92, C₂₇H₂₁ClN₂O₃) is a neurogenic inducer. It is soluble in DMSO (up to 45.69 mg/mL). The compound shows a purity of ≥95%. Detailed pharmacokinetic parameters are not extensively reported. The compound is typically stored at -20°C. It is for research purposes.
|
| Toxicity/Toxicokinetics |
Toxicology data for Neurodazine are limited in publicly available sources. As a neurogenic inducer, potential effects on normal neural development should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
2-[5-(3-chlorophenyl)-2-furanyl]-4,5-bis(4-methoxyphenyl)-1H-imidazolium is a member of the imidazolium class of compounds.
Neurodazine is a research-grade neurogenic inducer for studying neurogenesis and neuroprotection. Its primary applications include neuroscience, stem cell biology, and drug discovery. The compound is not approved for clinical use and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves activation of Wnt and Shh signaling pathways and protection against oxidative stress. |
| Molecular Formula |
C27H25CLN2O3
|
|---|---|
| Molecular Weight |
460.95200
|
| Exact Mass |
460.155
|
| CAS # |
937807-66-4
|
| PubChem CID |
16112820
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
669.0±55.0 °C at 760 mmHg
|
| Flash Point |
358.4±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.613
|
| LogP |
6.42
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
608
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FEEOFPAEDSMOTO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H21ClN2O3/c1-31-21-10-6-17(7-11-21)25-26(18-8-12-22(32-2)13-9-18)30-27(29-25)24-15-14-23(33-24)19-4-3-5-20(28)16-19/h3-16H,1-2H3,(H,29,30)
|
| Chemical Name |
2-[5-(3-chlorophenyl)furan-2-yl]-4,5-bis(4-methoxyphenyl)-1H-imidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~218.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.47 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.47 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1694 mL | 10.8472 mL | 21.6943 mL | |
| 5 mM | 0.4339 mL | 2.1694 mL | 4.3389 mL | |
| 10 mM | 0.2169 mL | 1.0847 mL | 2.1694 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
